Market news

CAS, a division of the American Chemical Society, today announced a collaboration with Novartis Biomedical Research focused on enhancing reaction data accessibility and supporting AI-enabled research. The initiative will leverage CAS unique scientific data curation expertise and science-smart technology to give Novartis researchers integrated, searchable access to proprietary experimental reaction data alongside more than 160 million+ scientist-curated reactions from the authoritative CAS Conten

On September 18, Novartis AG (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) to treat polymyalgia rheumatica (PMR) in adults who respond inadequately to steroids or relapse during tapering. Following this recommendation, the European Commission is expected to issue a […]

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)’ 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker’s board to improve oversight of its acquisitions, after Novartis shares suffered an 11% one-day drop this week. It wiped out nearly $30 billion in market value and erased all of […]

Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset. The deal gives Novartis worldwide rights to develop and commercialise the BoomRay program as part of its radiopharmaceutical pipeline. The agreement adds another early stage oncology candidate to Novartis' radioligand therapy efforts, expanding its presence in targeted cancer treatments. This new BoomRay radioligand license sits within a wider pattern...

Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]

Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive global license agreement with Novartis Pharma AG ("Novartis") for an undisclosed preclinical RLT asset.

Novartis AG (NYSE:NVS) has discontinued development of VHB937, also known as lifonebart, after the experimental ALS drug failed to meet both its primary and secondary endpoints in a Phase II trial involving 251 patients with early-stage ALS. The drug targeted TREM2, a protein involved in immune responses and inflammation in the brain. Novartis will stop […]

Novartis (SWX:NOVN) agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier. The transaction expands Novartis' toolkit for research into central nervous system disorders where treatment options remain limited. Novartis' move to secure Sironax's brain delivery platform sits against a wider backdrop our research...

Novartis (SWX:NOVN) is back in focus after the European Medicines Agency's CHMP issued a positive opinion for Cosentyx in polymyalgia rheumatica, highlighting both the product portfolio and the wider immunology pipeline. Recent trading has been choppy. The share price is down about 9.5% over the past month but still shows a 6.1% gain year to date, while the 1-year total shareholder return of 21.3% points to momentum that has been building over a longer stretch. Scan how Novartis fits into the...

On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1. It marked the company’s third clinical setback in a week following the earlier failure of cardiovascular drug pelacarsen […]

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.

Novartis (NVS) halts the development of ALS drug VHB937 after a Phase 2 trial failure, adding to recent study setbacks. Read more here.

Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

Legend’s new CEO Ingrid Zhang most recently served as chief commercial officer for Novartis International.

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa and marks just the first step in a […]

During the September 8 episode of Mad Money, Jim Cramer said Amgen Inc. (NASDAQ:AMGN) may have limited downside after the stock suffered its steepest one-day decline in more than two decades following disappointing cardiovascular trial results from Novartis. Finally, there’s Amgen. Admittedly, this one takes a little bit of fortitude. It was down 44 points […]

Novartis AG (NYSE:NVS) has suffered a major setback after its experimental drug del-desiran failed a late-stage trial for myotonic dystrophy type 1, a rare muscle-wasting disease with no approved treatments. The drug failed to show a statistically significant improvement over placebo on the trial’s primary endpoint, video hand opening time. Del-desiran was one of the key […]

By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) - Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs

Novartis AG’s (NYSE:NVS) pelacarsen failed an important test. Although the experimental medicine lowered lipoprotein(a), or Lp(a), it did not produce a statistically significant reduction in cardiovascular events in the Phase 3 Lp(a)HORIZON study. Bank of America does not believe the result breaks the Novartis (NYSE:NVS) investment thesis. The firm estimates that the failed study creates […]

Novartis AG (NYSE:NVS) has reported the first major success from three closely watched pipeline programs expected to produce clinical data in 2026. Its oral drug remibrutinib outperformed Sanofi’s older multiple-sclerosis treatment teriflunomide in reducing relapses across two late-stage studies. The results strengthen remibrutinib’s case as a potential growth driver while Novartis (NYSE:NVS) faces generic pressure […]

A top-20 shareholder wants an acquisition committee after two trial failures punished Novartis's dealmaking record.

Novartis faces shareholder pressure after phase 3 failures and M&A disappointments. Read more here.

These are the stocks posting the largest moves in the premarket.

ZURICH, Sept 10 (Reuters) - A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered ‌a record fall this week following back-to-back trial setbacks. David Samra, managing director at Artisan Partners and founding ‌partner of International Value Group, said successive chairmen had failed Novartis on acquisitions and that the company needed to change how it oversees deals.

Amgen raised full-year 2026 revenue and EPS guidance, signaling improved confidence. Find out why AMGN stock is upgraded to buy.

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently […]